{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:38:27Z","timestamp":1770431907271,"version":"3.49.0"},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,4,4]],"date-time":"2005-04-04T00:00:00Z","timestamp":1112572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:\u2002<\/jats:bold>\n                    The objective of this study is to assess the effects of sibutramine on body weight, body fat distribution, insulin resistance, plasma leptin, lipid profile and blood pressure profiles in hypertensive obese patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Eighty\u2010six central obese hypertensive patients (BMI\u2003=\u200339\u2003\u00b1\u20035\u2003kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , 84% of women, 48\u2003\u00b1\u20038.5 years old) were placed on a hypocaloric diet and placebo therapy for 4 weeks. They were then randomized to receive sibutramine (10\u2003mg) or placebo for 24 weeks. Both, before therapy and at the end of the study, the waist and hip circumferences were measured and the waist\/hip ratio (WHR) was calculated; abdominal ultrasonography was performed in order to estimate the amount of subcutaneous fat (SF) and visceral fat (VF), and the visceral\/subcutaneous ratio. Beyond HOMA\u2010r, another insulin resistance index (IRIp) was calculated by means of the formula: peak of blood glucose after oral glucose load\u2003\u00d7\u2003plasma insulin level\/10\n                    <jats:sup>4<\/jats:sup>\n                    . Fasting plasma leptin and lipid levels were also determined.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Sibutramine induced greater weight reduction than placebo (6.7 vs. 2.5%, p\u2003&lt;\u20030.001). Reductions in WHR (0.97\u2003\u00b1\u20030.08 vs. 0.94\u2003\u00b1\u20030.07, p\u2003&lt;\u20030.01), IRIp (0.11\u2003\u00b1\u20030.07 vs. 0.09\u2003\u00b1\u20030.06\u2003mmol\u2003\u03bc\/l\n                    <jats:sup>2<\/jats:sup>\n                    ) and VF (6.4\u2003\u00b1\u20032.4\u20136.0\u2003\u00b1\u20032.4\u2003cm, p\u2003&lt;\u20030.01) were observed only with sibutramine. Plasma leptin decreased with placebo (24\u2003\u00b1\u200315 vs. 18\u2003\u00b1\u200310\u2003UI\/l, p\u2003&lt;\u20030.01), but not with sibutramine (18.8\u2003\u00b1\u20038.4 vs. 18.2\u2003\u00b1\u200313.2\u2003UI\/l). No clinically significant change in lipid profile was observed in both groups. Moreover, office and 24\u2010h blood pressure values did not change during placebo or sibutramine therapy, whereas a significant increase in office heart rate, from 78.3\u2003\u00b1\u20037.3\u201382\u2003\u00b1\u20037.9\u2003b.p.m., p\u2003=\u20030.02, was observed with sibutramine.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    Sibutramine therapy induced greater body weight loss than placebo in hypertensive obese patients. This was associated with WHR reduction, decreases in VF and insulin resistance. The maintenance of leptin levels during sibutramine therapy may be important to avoid weight recovery, although this finding must be confirmed by other prospective studies.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2005.00465.x","type":"journal-article","created":{"date-parts":[[2005,4,4]],"date-time":"2005-04-04T10:51:59Z","timestamp":1112611919000},"page":"246-253","source":"Crossref","is-referenced-by-count":20,"title":["Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients"],"prefix":"10.1111","volume":"7","author":[{"given":"A. N.","family":"Faria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. F.","family":"Ribeiro Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. E.","family":"Kohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Gouvea Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,4,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500040049035"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111040"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602083340607"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800832"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801508"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111133"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(94)00206-Q"},{"key":"e_1_2_6_9_2","first-page":"541","article-title":"Promising new approaches","volume":"1","author":"Reasner CA","year":"1999","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800504"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:13:2:207"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0022-3565(24)37090-9","article-title":"In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor","volume":"283","author":"Grundlah C","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18319"},{"key":"e_1_2_6_14_2","first-page":"505","article-title":"Randomized placebo\u2010controlled trial of long\u2010term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith IG","year":"2001","journal-title":"J Fam Pract"},{"key":"e_1_2_6_15_2","first-page":"272","article-title":"Sibutramine trial of obesity reduction and maintenance \u2013 efficacy during the six\u2010month run\u2010in phase","volume":"22","author":"Finer N","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00071.x"},{"key":"e_1_2_6_17_2","first-page":"172","article-title":"The effects of sibutramine in the treatment of obesity in patients with arterial hypertension","volume":"78","author":"Faria AN","year":"2001","journal-title":"Arq Bras Cardiol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.199"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1381\/096089202321019620"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802398"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.38.3.713"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1088\/0967-3334\/22\/2\/308"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800693"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)00236-3"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789x.2000.00020.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.117510"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.1.137"},{"key":"e_1_2_6_29_2","first-page":"29","article-title":"Impaired microvascular function in obesity. Implications for obesity\u2010associated microangiopathy, hypertension and insulin resistance","volume":"25","author":"De Jongh RT","year":"2004","journal-title":"Circulation"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/152308603764816505"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119636"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2329"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.7.1101"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01508-3"},{"key":"e_1_2_6_35_2","first-page":"359","article-title":"Apolipoprotein B levels and related factors in a rural white South African community \u2010 the CORIS Study. Coronary Risk Factor Study","volume":"86","author":"Steyn K","year":"1996","journal-title":"S Afr Med J"},{"key":"e_1_2_6_36_2","first-page":"S38","article-title":"Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal\/visceral fat reduction?","volume":"22","author":"Van Gaal LF","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_6_37_2","first-page":"847","article-title":"Sonography detection of small intra\u2010abdominal fat variation","volume":"15","author":"Armellini F","year":"1991","journal-title":"Int J Obes"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.2.347"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.8.2685"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00697.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-200108000-00010"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2000.279.6.R2222"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.24220"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801059"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1998.tb00324.x"},{"key":"e_1_2_6_46_2","first-page":"2935","article-title":"The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial","volume":"163","author":"Toubro S","year":"2001","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00411-2"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2005.00465.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2005.00465.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:00:31Z","timestamp":1761876031000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2005.00465.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,4]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1463-1326.2005.00465.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2005.00465.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,4]]}}}